Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC Capital Starts Centene (CNC) at Sector Perform
• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand